JP2005522503A5 - - Google Patents

Download PDF

Info

Publication number
JP2005522503A5
JP2005522503A5 JP2003583994A JP2003583994A JP2005522503A5 JP 2005522503 A5 JP2005522503 A5 JP 2005522503A5 JP 2003583994 A JP2003583994 A JP 2003583994A JP 2003583994 A JP2003583994 A JP 2003583994A JP 2005522503 A5 JP2005522503 A5 JP 2005522503A5
Authority
JP
Japan
Prior art keywords
solvent
nateglinide
crystalline form
room temperature
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003583994A
Other languages
English (en)
Japanese (ja)
Other versions
JP4615866B2 (ja
JP2005522503A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/003864 external-priority patent/WO2003087038A1/en
Publication of JP2005522503A publication Critical patent/JP2005522503A/ja
Publication of JP2005522503A5 publication Critical patent/JP2005522503A5/ja
Application granted granted Critical
Publication of JP4615866B2 publication Critical patent/JP4615866B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003583994A 2002-04-15 2003-04-14 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形 Expired - Fee Related JP4615866B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37262502P 2002-04-15 2002-04-15
PCT/EP2003/003864 WO2003087038A1 (en) 2002-04-15 2003-04-14 Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010156749A Division JP2010265295A (ja) 2002-04-15 2010-07-09 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形

Publications (3)

Publication Number Publication Date
JP2005522503A JP2005522503A (ja) 2005-07-28
JP2005522503A5 true JP2005522503A5 (https=) 2006-06-01
JP4615866B2 JP4615866B2 (ja) 2011-01-19

Family

ID=29250881

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003583994A Expired - Fee Related JP4615866B2 (ja) 2002-04-15 2003-04-14 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
JP2010156749A Pending JP2010265295A (ja) 2002-04-15 2010-07-09 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010156749A Pending JP2010265295A (ja) 2002-04-15 2010-07-09 Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形

Country Status (8)

Country Link
US (3) US7247746B2 (https=)
EP (1) EP1497258A1 (https=)
JP (2) JP4615866B2 (https=)
CN (1) CN1304366C (https=)
AU (1) AU2003242520A1 (https=)
BR (1) BR0309210A (https=)
CA (1) CA2482669A1 (https=)
WO (1) WO2003087038A1 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
WO2004020396A1 (en) * 2002-08-28 2004-03-11 Dr. Reddy's Laboratories Limited Crystalline form of nateglinide and process for preparation thereof
US7449519B2 (en) * 2003-02-18 2008-11-11 Konishi Co., Ltd. Curing resin, method for producing same and curing resin composition
HU227073B1 (hu) * 2003-07-10 2010-06-28 Richter Gedeon Nyrt Eljárás királisan tiszta N-(transz-4-izopropil-ciklohexilkarbonil)-D-fenil-alanin (nateglinid) és kristálymódosulatainak elõállítására, valamint a G-kristálymódosulata
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
EP2847161A4 (en) * 2012-05-08 2015-12-23 Cellix Bio Private Ltd COMPOSITIONS AND METHOD FOR TREATING DIABETES
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
CN109100430A (zh) * 2017-06-20 2018-12-28 珠海同益制药有限公司 一种那格列奈手性异构体色谱分析方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5463116A (en) * 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
ES2100291T3 (es) * 1991-07-30 1997-06-16 Ajinomoto Kk Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos.
WO2003022251A1 (en) 2001-09-12 2003-03-20 Alembic Limited Novel stable crystal form of n-trans-4-isopropylcyclohexyl carbonyl)-d-phenylalanine and process of preparation
JP4538842B2 (ja) * 2002-04-15 2010-09-08 味の素株式会社 新規ナテグリニド結晶

Similar Documents

Publication Publication Date Title
JP2005522503A5 (https=)
JP4615866B2 (ja) Ｎ−（トランス−４−イソプロピルシクロヘキシルカルボニル）−ｄ−フェニルアラニンの結晶形
CN1483018A (zh) 那格列奈b型结晶的制造方法
RU2007114127A (ru) Полиморфы ингибитора цистеинпротеазы n-(1-цианоциклопропил)-3-циклопропилметансульфонил-2(r)-(2,2,2-трифторо-1(s)-(4-фторфенил) этиламино) пропионамида
JP2009541334A5 (https=)
JP2005503386A5 (https=)
JP2005509025A5 (https=)
JP2010090174A (ja) 新規ナテグリニド結晶
JP4180368B2 (ja) 塩酸ベンラファキシンの結晶形
CN109456341B (zh) 一类具有炔基或叠氮基衍生位点的磺酰胺罗丹明化合物及制备方法与应用
JPS63301846A (ja) Ｈｎｓ２の純度を有するｈｎｓの製造法
CN102046594A (zh) 2-氨基-2-[2-[4-(3-苄氧基苯硫基)-2-氯苯基]乙基]-1，3-丙二醇盐酸盐的结晶化方法
JPH06509113A (ja) クロロアセチルクロリドを用いたイオベルソールの合成
CN110418797B (zh) 一种制备酮内酯化合物的方法
JP2004002230A (ja) 微水ベンズイミダゾール系化合物の製法
CN101193857A (zh) 方法和化合物
JP2009525329A (ja) レミフェンタニル塩酸塩の結晶形
CN108238609B (zh) 一种四水八硼酸钠的制备方法
CN100355769C (zh) 2＇－甲氧基腺苷的制备方法
CN108250255A (zh) 一种提高三氯蔗糖-6-乙酯结晶收率的方法
CN110698398A (zh) 一种米库氯铵的纯化方法
CN109456219B (zh) 一种稳定高效制备n-丙烯酰胺类化合物的方法
JP2004196796A5 (https=)
CN111247127B (zh) 用于合成药物的中间体化合物的生产方法
CN106008629A (zh) 泰地罗新1,4-二氧六环溶剂化合物及制备方法